2.74
-0.07(-2.49%)
Currency In USD
| Previous Close | 2.81 |
| Open | 2.73 |
| Day High | 2.78 |
| Day Low | 2.67 |
| 52-Week High | 5.23 |
| 52-Week Low | 2.01 |
| Volume | 1.48M |
| Average Volume | 3.46M |
| Market Cap | 412.02M |
| PE | -3.01 |
| EPS | -0.91 |
| Moving Average 50 Days | 3.1 |
| Moving Average 200 Days | 3.1 |
| Change | -0.07 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $126.91 as of March 01, 2026 at a share price of $2.74. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $1,363.18 as of March 01, 2026 at a share price of $2.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report b
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 16, 2025 1:00 PM GMT
VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
GlobeNewswire Inc.
Dec 11, 2025 1:00 PM GMT
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular miniaturization and drive vellus-to-terminal hair reg